Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Bladder Cancer

Free Subscription Articles published in Anticancer Res Retrieve available abstracts of 34 articles: HTML format

Single Articles

August 2025
1. ZHENG M, Lu J, Yu W, Li Y, et al
   Nucleoporin 188 as a Predictive Biomarker of Poor Prognosis in Muscle-invasive Bladder Cancer.
   Anticancer Res. 2025;45:3245-3261.
   PubMed     Abstract available
   
   
   
2. OKADA K, Naito Y, Irie S, Nakamoto C, et al
   Novel UF-5000-based Detection, Integrating Inflammatory Parameters, for Urothelial Carcinoma of the Urinary Bladder.
   Anticancer Res. 2025;45:3531-3541.
   PubMed     Abstract available
   
   
   June 2025
3. MATSUO T, Miyata Y, Harada J, Itoh I, et al
   Efficacy of Pembrolizumab as Second or Third-line Therapy for Local Advanced and Metastatic Urothelial Cancer.
   Anticancer Res. 2025;45:2563-2573.
   PubMed     Abstract available
   
   
   
4. ONISHI T, Sekito S, Shibahara T, Yabana T, et al
   Randomized Study of Short-time Continuous Saline Irrigation After Transurethral Resection in Non-muscle Invasive Bladder Cancer.
   Anticancer Res. 2025;45:2653-2660.
   PubMed     Abstract available
   
   
   May 2025
5. FURUBAYASHI N, Mochida M, Kijima A, Fujimoto Y, et al
   Treatment Outcomes After Progression With Enfortumab Vedotin in Patients With Advanced Urothelial Carcinoma.
   Anticancer Res. 2025;45:2185-2193.
   PubMed     Abstract available
   
   
   
6. TUNG CH, Lin SH, Chang KP, Xu YW, et al
   Light Bladder Net: Non-invasive Bladder Cancer Prediction by Weighted Deep Learning Approaches and Graphical Data Transformation.
   Anticancer Res. 2025;45:1953-1964.
   PubMed     Abstract available
   
   
   March 2025
7. YAMAGUCHI N, Morizane S, Yamane H, Shimizu R, et al
   Perioperative and Oncologic Outcomes of Robot-assisted Versus Laparoscopic Radical Cystectomy in Patients With Bladder Cancer.
   Anticancer Res. 2025;45:1215-1224.
   PubMed     Abstract available
   
   
   December 2024
8. JARADAT JH, Idrissi YA, Saeed A
   HOOK3 Amplification in Bladder Urothelial Carcinoma: Insights from Gene Expression and Survival Analysis.
   Anticancer Res. 2024;44:5175-5185.
   PubMed     Abstract available
   
   
   October 2024
9. DIONESE M, Bimbatti D, Pierantoni F, Lai E, et al
   Systemic Inflammation Indexes and Risk of Immune-related Adverse Events in Patients With Metastatic Urothelial Carcinoma Treated With Immunotherapy.
   Anticancer Res. 2024;44:4379-4386.
   PubMed     Abstract available
   
   
   September 2024
10. SATO M, Sato T, Hozumi C, Han Q, et al
    [(11)C]Methionine PET vs. [(18)F]Fluorodeoxyglucose PET Whole-body Imaging to Determine the Extent of Methionine-addiction Compared to Glucose-addiction of Primary and Metastatic Cancer of the Trunk in Patients.
    Anticancer Res. 2024;44:3891-3898.
    PubMed     Abstract available
    
    
    August 2024
11. ZEKAN D, Hogan T, Jackson B, Jackson G, et al
    The Novel Platinum Analog Dicycloplatin Provides Reliable Growth Inhibition of Urothelial Carcinoma Cells In Vitro.
    Anticancer Res. 2024;44:3243-3254.
    PubMed     Abstract available
    
    
    May 2024
12. CHEN CH, Chen YC, Chang YC, Hung CH, et al
    Taurine Rescues Cancer-induced Atrophy in Human Skeletal Muscle Cells via Ameliorating the Inflammatory Tumor Microenvironment.
    Anticancer Res. 2024;44:1963-1971.
    PubMed     Abstract available
    
    
    
13. KOBATAKE K, Ikeda K, Kohada Y, Tasaka R, et al
    Muscle-Invasive Bladder Cancer With Hydronephrosis Exhibits a High Frequency of Mutations in Fibroblast Growth Factor Receptor 3 Gene.
    Anticancer Res. 2024;44:1947-1954.
    PubMed     Abstract available
    
    
    
14. HUBER F, Wolf I, Storz J, Schultze-Seemann S, et al
    Antibody-dye Conjugates Targeting EGFR and HER2 for the Photoimmunotherapy of Bladder Cancer.
    Anticancer Res. 2024;44:1837-1844.
    PubMed     Abstract available
    
    
    
15. FUKUOKAYA W, Akazawa K, Kimura T
    Association Between Serum Magnesium Levels and Outcomes of Atezolizumab in Patients With Metastatic Urothelial Carcinoma.
    Anticancer Res. 2024;44:2117-2123.
    PubMed     Abstract available
    
    
    
16. FUCHIZAWA H, Ando K, Motoi N, Iizuka T, et al
    STAT3 Contributes a Favorable Response to Pembrolizumab Through IFN-gamma-induced Apoptosis in Urothelial Cancer.
    Anticancer Res. 2024;44:1925-1930.
    PubMed     Abstract available
    
    
    April 2024
17. SATO R, Watanabe K, Matsushita Y, Watanabe H, et al
    Assessment of Therapeutic Effects of Combined Treatment With Cisplatin and Anti-mouse Programmed Death (PD)-1 Antibody in a Mouse Urothelial Cancer Model.
    Anticancer Res. 2024;44:1417-1423.
    PubMed     Abstract available
    
    
    
18. FURUBAYASHI N, Minato A, Tomoda T, Hori Y, et al
    Change in the Neutrophil-to-Eosinophil Ratio After Avelumab Maintenance for Advanced Urothelial Carcinoma: The UROKYU Study.
    Anticancer Res. 2024;44:1675-1681.
    PubMed     Abstract available
    
    
    March 2024
19. YU SH, Wang CY, Wang SS, Li JR, et al
    Comparing Clinical Efficacy of Different Bacillus Calmette-Guerin Strains in Patients With T1 High Grade Bladder Cancer.
    Anticancer Res. 2024;44:1299-1307.
    PubMed     Abstract available
    
    
    
20. SHINDO T, Hashimoto K, Takahashi A, Miyamoto S, et al
    Comparison of Oncological Outcomes of Pembrolizumab as Second-line Therapy and Maintenance Avelumab Therapy in Advanced Urothelial Carcinoma After Platinum-based Chemotherapy.
    Anticancer Res. 2024;44:1271-1279.
    PubMed     Abstract available
    
    
    February 2024
21. ONER M, Lin E, Chiu KY, Chen MC, et al
    p35/CDK5 Regulates Bladder Cancer Proliferation and Migration and Promotes Higher Tumor Grade and Poor Survival Rate in Patients With Bladder Cancer.
    Anticancer Res. 2024;44:543-553.
    PubMed     Abstract available
    
    
    December 2023
22. FURUBAYASHI N, Minato A, Tomoda T, Hori Y, et al
    Organ-specific Tumor Response to Avelumab Maintenance Therapy for Advanced Urothelial Carcinoma: A Multicenter Retrospective Study.
    Anticancer Res. 2023;43:5689-5698.
    PubMed     Abstract available
    
    
    November 2023
23. NISHIYAMA N, Kita Y, Ito K, Kato M, et al
    Second-line Pembrolizumab for Metastatic Urothelial Carcinoma: Differences in Treatment Outcomes According to the Primary Site.
    Anticancer Res. 2023;43:5041-5050.
    PubMed     Abstract available
    
    
    October 2023
24. SOMMER U, Grosser M, Aust D, Joehrens K, et al
    PD-L1 mRNA Detection in Immunohistochemically Negative Patients: A Complementary Method for a Better Treatment Selection?
    Anticancer Res. 2023;43:4365-4371.
    PubMed     Abstract available
    
    
    September 2023
25. MINATO A, Kimuro R, Ohno D, Tanigawa K, et al
    Efficacy and Tolerability of Enfortumab Vedotin for Metastatic Urothelial Carcinoma: Early Experience in the Real World.
    Anticancer Res. 2023;43:4055-4060.
    PubMed     Abstract available
    
    
    
26. KASHIWAGI E, Shiota M, Inokuchi J, Tsukahara S, et al
    Comparison of Testosterone Level of Seminal Vesicle Fluid in Patients With Prostate Cancer Versus Other Malignancies.
    Anticancer Res. 2023;43:4249-4254.
    PubMed     Abstract available
    
    
    August 2023
27. TACHIBANA M, Tsubouchi K, Fukuhara Y, Aoyagi C, et al
    Factors Related to Overactive Bladder-like Symptoms in Bladder Cancer.
    Anticancer Res. 2023;43:3607-3613.
    PubMed     Abstract available
    
    
    
28. ARAI T, Sazuka T, Oka R, Tsukamoto R, et al
    Investigation on the Usefulness of Photodynamic Diagnosis-assisted Targeted Bladder Biopsy: Japanese Real-world Study.
    Anticancer Res. 2023;43:3615-3621.
    PubMed     Abstract available
    
    
    May 2023
29. SANO T, Aizawa R, Ito K, Nakamura K, et al
    Efficacy and Tolerability of Second-line Pembrolizumab With Radiation Therapy in Advanced Urothelial Carcinoma.
    Anticancer Res. 2023;43:2119-2126.
    PubMed     Abstract available
    
    
    April 2023
30. YAMAGUCHI N, Morizane S, Yumioka T, Shimizu R, et al
    Effect of Adjuvant Systemic Chemotherapy on Intravesical Recurrence After Radical Nephroureterectomy for Upper Urinary Tract Urothelial Carcinoma.
    Anticancer Res. 2023;43:1725-1730.
    PubMed     Abstract available
    
    
    
31. LUZHA J, Nass N, Czapiewski P, Schroeder N, et al
    Expression of Eukaryotic Translation Initiation Factors in the Urothelial Carcinoma of the Bladder.
    Anticancer Res. 2023;43:1437-1448.
    PubMed     Abstract available
    
    
    
32. LEE YH, Wu RC, Mai HC, Huang WL, et al
    The Regulatory Role of Nuclear Respiratory Factor 1 in Bladder Cancer Cells.
    Anticancer Res. 2023;43:1521-1531.
    PubMed     Abstract available
    
    
    March 2023
33. CHEN SY, Chao CN, Huang HY, Zhao PW, et al
    Artesunate Exhibits Synergy With Cisplatin and Cytotoxicity for Upper Tract and Bladder Urothelial Carcinoma Cells.
    Anticancer Res. 2023;43:1175-1184.
    PubMed     Abstract available
    
    
    
34. LI JR, Wang SS, Lu K, Chen CS, et al
    First-line Chemotherapy Response Is Associated With Clinical Outcome During Immune Checkpoint Inhibitor Treatment in Advanced Urothelial Carcinoma: A Real World Retrospective Study.
    Anticancer Res. 2023;43:1331-1339.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Bladder Cancer is free of charge.